P501-AS15

**P501-AS15** is an investigational GSK therapeutic cancer vaccine comprising recombinant CPC-P501 protein, a modified fusion form of the prostate-specific P501 antigen, formulated with the AS15 immunostimulant adjuvant system. It was evaluated as first-line immunotherapy for patients with hormone-sensitive prostate cancer with rising prostate-specific antigen after primary treatment. AS15 contains CpG 7909, monophosphoryl lipid A, QS-21, and liposomes, intended to enhance antigen-specific humoral and cellular immune responses against P501-expressing prostate cancer cells. ([s3.amazonaws.com](https://s3.amazonaws.com/ctr-gsk-7381/102238/bd62abc7-23f5-4dba-b0cb-463d22df199c/cac2eb0e-c81c-448f-bb66-183b3f554377/gsk-102238-104634-clinical-study-report-redact-v1.pdf))

Other names

CPC-P501 protein formulated with AS15CPC-P-501 protein formulated with AS15CPC-P 501 protein formulated with AS15P501 AS15P-501 AS15P 501 AS15P501-AS15 vaccineP-501-AS15 vaccineP 501-AS15 vaccine